Citizens Rates BeOne Medicines (ONC) buy, $396 Price Target
Citizens reaffirmed its buy rating on BeOne Medicines AG, setting a target price of $396, a 38.96% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citizens rated BeOne Medicines AG ($ONC) "buy" with a $396 price target on July 1, 2026.
Since the rating, $ONC is up 3.8% after 1 week, up 8.7% after 1 month and up 26.9% to date (from the $290.74 close on Jul 1, 2026).
ONC
BeOne Medicines AG
Key Points
- Citizens reiterated its buy rating for BeOne Medicines AG (ONC) with a price target of $396 on July 1, 2026.
- Citizens's $396 price target implies 38.96% upside from BeOne Medicines AG's ($ONC) current $284.97 share price.
- BeOne Medicines, trading at $284.97 on Wednesday, has a market cap of $29.57 billion and a P/E ratio of 64.5.
- Insiders, including CEO John Oyler, recently sold shares, while analysts maintain a strong buy consensus.
Get $ONC trade alerts by text
We text you when insiders, Congress or big funds trade $ONC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BeOne Medicines AG alert may contain errors. Disclosures
Citizens reaffirmed its buy rating for BeOne Medicines AG (NasdaqGS: ONC) on July 1, 2026, setting a target price of $396. Shares of BeOne Medicines traded near $284.97 on Wednesday.
BeOne Medicines AG Stock Down 23.8%
Shares of NasdaqGS:ONC traded around $284.97 on Wednesday. BeOne Medicines AG has a market cap of approximately $29.57 billion and a P/E ratio of 64.5. The stock has a 52-week low of $239.25 and a high of $385.22. It boasts a 50-day moving average of $291.34 and a 200-day moving average of $316.66. The company maintains a healthy current ratio of 3.64 and a quick ratio of 3.17, with a debt-to-equity ratio of 43.13.
$ONC price target
BeOne Medicines AG daily closes and this analyst's $396 target. Not advice.
Recent Earnings
For its latest quarter, BeOne Medicines reported revenue of $5.74 billion, reflecting a growth of 35.5%. The company achieved a net margin of 8.9% and a return on equity of 12.4%. Earnings per share were $4.42. The next earnings release is scheduled for August 5, 2026.
Insider Buying and Selling at BeOne Medicines AG
Several insiders at BeOne Medicines have recently sold shares. CEO John Oyler sold 3,410 shares at an average price of $273.78 on June 23, 2026, and 3,693 shares at $265.55 on June 16, 2026. President and COO Xiaobin Wu sold 1,292 shares at $276.26 on June 23, 2026, and 1,357 shares at $266.76 on June 16, 2026. These transactions were not part of any pre-scheduled trading plans.
Analysts Set New Price Targets
On July 1, 2026, Citizens reiterated its buy rating for BeOne Medicines with a target price of $396. Other analysts have also shown confidence in the stock, with RBC Capital maintaining a buy rating and a target of $436 on June 2, 2026. Leerink Partners maintained a buy rating with a $367 target on May 15, 2026. Currently, the stock has a strong buy consensus, with an average target price of $412.35 among 27 analysts.
About BeOne Medicines AG
BeOne Medicines AG, headquartered in Basel, Switzerland, is a biotechnology company specializing in oncology treatments. It develops and markets products like BRUKINSA and TEVIMBRA for blood and solid tumor cancers, among others. The company operates globally, with a strong presence in the United States, China, and Europe. Led by CEO John V. Oyler, BeOne Medicines employs around 12,000 people.
Bottom Line
Citizens' reaffirmation of a buy rating for BeOne Medicines AG underscores continued analyst confidence in the company's growth prospects. With a strong product lineup and solid financials, BeOne remains a key player in the biotech sector. Investors should note that analyst ratings are forward-looking and based on current projections.
Related Filing Alerts
Source: Citizens's rating change on $ONC (Jul 1, 2026). Written by software, not financial advice. How we make alerts